Modulating RNA epigenetics

Sunday 2 May 2021

United Kingdom

Preclinical work being undertaken by STORM Therapeutics Ltd has shown that targeting RNA modifying enzymes with small molecule drugs is a credible new strategy for treating acute myeloid leukaemia, as well as solid tumours. A second paper outlining this strategy was published on 26 April 2021 in the journal Nature.